Ge healthcare acquires zionexa; molecular imaging agent aims to enable more targeted treatment for metastatic breast cancer patients

Marlborough, mass.--(business wire)--ge healthcare today announced the acquisition of zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. the company aims to develop and bring to market zionexa's pipeline biomarkers, as well as the recently fda-approved pet imaging agent, cerianna™ (fluoroestradiol f-18), which is used as an adjunct to biopsy for the detection of estrogen receptor (er) positive lesions to help inform treatment
GE Ratings Summary
GE Quant Ranking